Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Accumulated Expenses (2024 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Other Accumulated Expenses for 2 consecutive years, with $588000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 1300.0% to $588000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $588000.0 through Dec 2025, up 1300.0% year-over-year, with the annual reading at $588000.0 for FY2025, 1300.0% up from the prior year.
  • Other Accumulated Expenses hit $588000.0 in Q4 2025 for ARS Pharmaceuticals, down from $3.1 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $3.1 million in Q3 2025 to a low of $42000.0 in Q4 2024.